Harmony Biosciences Commented On The Favorable Decision By The U.S. Patent And Trademark Office To Deny A Petition For Reexamination Concerning A Patent Covering The Active Ingredient In Wakix (Pitolisant)
Portfolio Pulse from Benzinga Newsdesk
The U.S. Patent and Trademark Office has denied a petition for reexamination of a patent covering the active ingredient in Wakix (Pitolisant), a product of Harmony Biosciences. This decision is favorable for Harmony Biosciences.
August 28, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The denial of a petition for reexamination of a patent covering the active ingredient in Wakix by the U.S. Patent and Trademark Office is a positive development for Harmony Biosciences.
The denial of a petition for reexamination of a patent is a positive development for the patent holder. This decision secures Harmony Biosciences' exclusive rights to the active ingredient in Wakix, potentially preventing competition and ensuring continued revenue from this product. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100